Metformin and ageing: can treatment delay age-related diseases?
Abstract
Metformin is the most widely used medication for diabetes. In recent years, metformin has attracted attention because it might slow down aging. By direct interference with aging-related processes such as reduced autophagy, the accumulation of DNA damage and inflammation, metformin could reduce the risk of age-related diseases including cardiovascular diseases, cancer and neurodegenerative diseases. This article describes the clinical and translational perspectives of metformin in view of the underlying molecular mechanisms. Similarities and differences between lifestyle interventions such as exercise and therapeutic fasting will be highlighted. Upon a careful evaluation of the known advantages and disadvantages, it can be considered to implement metformin use in specific cases for preventive purposes.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.